Comparison of a Vasopeptidase Inhibitor with Neutral Endopeptidase and Angiotensin-Converting Enzyme Inhibitors on Bradykinin Metabolism in the Rat Coronary Bed
- 1 April 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 37 (4) , 359-366
- https://doi.org/10.1097/00005344-200104000-00002
Abstract
The in vitro effects of omapatrilat, a dual vasopeptidase inhibitor that simultaneously inhibits neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), on exogenous bradykinin metabolism after a single passage through the coronary bed were compared with that of a NEP inhibitor (retrothiorphan, 25 n M), an ACE inhibitor (enalaprilat, 130 n M), and omapatrilat (25 n M). Bradykinin and inhibitors were infused into isolated Langendorff rat hearts perfused at 1 ml/min followed by reperfusion at 10 ml/min. Residual bradykinin was quantified in the coronary effluent by enzyme-linked immunosorbent assay to calculate bradykinin recovery and its kinetic parameters (Vmax/Km). Bradykinin degradation rate at 1 ml/min was 4.56 ± 0.39 1/min per gram without inhibitors and was significantly reduced to 2.57 ± 0.19 1/min per gram in the presence of enalaprilat, to 2.97 ± 0.38 1/min per gram with retrothiorphan, to 1.82 ± 0.17 1/min per gram with both enalaprilat and retrothiorphan, and to 1.14 ± 0.35 1/min per gram with omapatrilat. In a second set of experiments, the effect of a 14-day treatment of rats with either ACE inhibitors (enalapril, quinapril, and ramipril), a NEP inhibitor (candoxatril), or omapatrilat on exogenous bradykinin metabolism was studied in Langendorff perfused hearts isolated from these long-term treated rats. In untreated rats, bradykinin degradation at a coronary perfusion of 1 ml/min was 4.35 ± 0.41 1/min per gram. This value was reduced by 30% for the NEP inhibitor, by 50% for all ACE inhibitors, and by 75% for omapatrilat. All inhibitors administered either short term or long term significantly reduced bradykinin degradation during a single passage through the coronary bed. However, omapatrilat administration resulted in the greatest protection from bradykinin breakdown than ACE or NEP inhibitors alone.Keywords
This publication has 16 references indexed in Scilit:
- Metabolism of bradykinin by the rat coronary vascular bedCardiovascular Research, 1998
- Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levelsEuropean Journal of Pharmacology, 1998
- Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activationJournal of Immunological Methods, 1995
- Development of digoxigenin-labeled peptide: Application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissuesPeptides, 1994
- Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers.Circulation Research, 1992
- Bradykinin-Degrading Enzymes: Structure, Function, Distribution, and Potential Roles in Cardiovascular PharmacologyJournal of Cardiovascular Pharmacology, 1992
- Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives?Trends in Pharmacological Sciences, 1990
- Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: possible physiological significance.Proceedings of the National Academy of Sciences, 1990
- Assay of peptidase and protease enzymes in vivoBiochemical Pharmacology, 1983
- Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptidesBiochemistry, 1983